How Many People Take GLP-1: A Deep Dive into Usage Trends and Insights

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Approximately 9 million Americans are currently taking GLP-1 medications, representing a dramatic shift in how metabolic health is managed. This surge reflects growing clinical evidence and real-world success across diverse populations. PlexusDx helps individuals access personalized GLP-1 therapy without insurance requirements or membership fees.

Global GLP-1 Adoption and Market Growth

GLP-1 receptor agonist prescriptions have increased by over 1,200% in major markets since 2021. This expansion extends beyond diabetes management into weight loss and metabolic optimization. Compounded versions, manufactured in licensed 503A pharmacies, have democratized access by reducing barriers to entry and offering affordability comparable to specialty medications.

Market research indicates that GLP-1 users span all income levels, ages 25–75, and across urban and rural regions. Insurance limitations and prior authorization delays historically restricted access, but direct-to-consumer platforms like PlexusDx have shifted this landscape. Today, individuals can initiate treatment within days rather than weeks or months.

Demographics of GLP-1 Users

Women comprise roughly 60–65% of GLP-1 users, driven by higher obesity prevalence and greater engagement with preventive health strategies. Age distribution peaks between 35–55 years, though increasing numbers of individuals in their 60s and 70s are benefiting from these medications. Metabolic conditions like type 2 diabetes, prediabetes, and obesity-related cardiovascular risk drive most prescriptions.

Socioeconomic diversity has increased as compounded semaglutide and tirzepatide become accessible outside traditional insurance networks. Geographic adoption shows stronger penetration in urban centers, yet rural adoption is accelerating through telehealth platforms. PlexusDx serves all 50 states, ensuring equitable access regardless of location or insurance status.

Why GLP-1 Usage Continues to Rise

Clinical evidence demonstrates that GLP-1 agonists produce sustained weight loss of 15–22% of body weight over 68 weeks, significantly outperforming older weight management approaches. Beyond weight reduction, these medications improve blood sugar control, reduce cardiovascular event risk, and lower inflammatory markers. Real-world testimonials and social proof have accelerated interest among individuals previously skeptical of medication-based interventions.

Emerging research into dual-pathway compounds like tirzepatide—which activates both GLP-1 and GIP receptors—shows enhanced efficacy, driving demand for combination protocols. Microdose GLP-1 approaches offer additional flexibility for individuals seeking gentler introduction or maintenance. PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptides, allowing clinicians to predict individual response patterns and optimize compound selection.

Personalized GLP-1 Therapy and Genetic Insights

Not all GLP-1 users respond identically due to genetic variation in receptor sensitivity, hunger regulation, and glucose metabolism. Key genetic variants—including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—influence baseline appetite set-point and drug responsiveness. The Precision Peptide Genetic Test identifies which of 14 metabolic pathways most strongly regulate your weight and appetite, enabling truly personalized dosing strategies.

PlexusDx integrates genetic insights with clinical monitoring to optimize outcomes. Compounded semaglutide injections start at $149/month, with dosing flexibility that grows with your physiology—not your budget. Oral and injectable tirzepatide options, plus dual-compound GLP-Squared formulations, provide alternatives for patients with specific preferences or absorption considerations. The $99 Precision Peptide Genetic Test becomes available after your first treatment month, ensuring your therapy aligns with your metabolic blueprint.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many people are currently using GLP-1 medications in the United States?

Approximately 9 million Americans are taking GLP-1 medications for weight management, metabolic health, or diabetes control. This number has grown from roughly 600,000 in 2021, reflecting increased clinical confidence and expanded access through direct-to-consumer platforms. PlexusDx contributes to this accessibility by offering compounded semag...

What percentage of GLP-1 users are taking these drugs for weight loss versus diabetes?

Approximately 70–75% of current GLP-1 users take these medications primarily for weight management, while 25–30% address diabetes or prediabetes. This shift reflects growing recognition of GLP-1 agonists as effective weight loss tools independent of diabetes status. PlexusDx supports both populations with flexible dosing and pricing structures.

Are compounded GLP-1 medications from PlexusDx as safe as brand-name versions?

Compounded semaglutide and tirzepatide from licensed 503A pharmacies contain identical active pharmaceutical ingredients manufactured to the same standards as brand medications. The key difference is cost and accessibility—PlexusDx compounded versions start at $149/month for semaglutide injection, making them accessible without insurance. All fo...

How does the Precision Peptide Genetic Test improve GLP-1 outcomes?

The test analyzes 150+ genetic insights across 14 metabolic pathways, including appetite regulation, glucose handling, and receptor sensitivity genes like GLP1R rs6923761 and GIPR rs1800437. This data helps predict which GLP-1 formulation and dose range will work best for your specific biology. Available for $99 after your first month of treatme...

Can I use HSA or FSA funds to pay for PlexusDx GLP-1 medications?

Yes, all PlexusDx GLP-1 medications are HSA- and FSA-eligible, making them accessible to individuals using tax-advantaged health savings accounts. Combined with starting prices of $149/month for semaglutide injection, this option maximizes affordability. PlexusDx accepts these payment methods directly without requiring insurance approval or prio...